States make $26 billion opioid deal with major drug companies

2021 ◽  
Vol 33 (30) ◽  
pp. 6-7
Author(s):  
Alison Knopf
Keyword(s):  
Drug Companies ◽  
Major Drug

Pharmaceuticals and Europe 1992: The Dynamics of Industrial Change

1992 ◽  
Vol 24 (1) ◽  
pp. 33-48 ◽  
Author(s):  
J Howells
Keyword(s):  
Pharmaceutical Industry ◽  
Vertical Integration ◽  
Central Element ◽  
Industrial Change ◽  
Drug Companies ◽  
Sales And Marketing ◽  
Survival And Growth ◽  
Information Assets ◽  
Financial Power ◽  
Major Drug

This paper provides an analysis of the implications of 1992 on the European pharmaceutical industry and sets it within the wider restructuring of the industry. The creation of a single European pharmaceutical market will, however, be gradual and will often present conflicting tendencies. The response of the major drug companies to the period of rapid technological change associated with the development of biotechnology is assessed. Their financial power together with their control of key knowledge and information assets, in the form of R&D and sales and marketing networks, has been a central element in their survival and growth. It has been presented that the power of large firms in terms of control and vertical integration has shifted away from production to nonproduction assets.

scholarly journals High levels of used syringe use and unsafe sex among people who inject drugs in Kumasi, Ghana: an urgent call for a comprehensive harm reduction approach

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Lisa J. Messersmith ◽  
Rose Adjei ◽  
Jennifer Beard ◽  
Angela R. Bazzi ◽  
Joel J. Earlywine ◽  
...  
Keyword(s):  
Drug Use ◽  
Harm Reduction ◽  
Population Size ◽  
Sex Workers ◽  
People Who Inject Drugs ◽  
Syringe Sharing ◽  
Unsafe Sex ◽  
Lack Of Information ◽  
Sex With Men ◽  
Major Drug

Abstract Background Drug use is a growing concern in Ghana. People who inject drugs (PWID) are highly vulnerable to HIV and other infectious diseases. Ghana’s National Strategic Plan for HIV/AIDS 2016–2020 identifies PWID as a key population, but efforts to address the needs of PWID have lagged behind those targeting sex workers and men who have sex with men. Lack of information about PWID is a critical barrier to implementing effective HIV prevention and treatment. We aimed to learn more about the vulnerability of the PWID population in order to inform much-needed harm reduction interventions. Methods From April to July 2018, we conducted a mixed methods study in Kumasi, Ghana, to identify all major drug using locations, count the numbers of PWID to obtain rough population size estimations, and administer anonymous surveys to 221 PWID regarding drug use and sexual behavior. We also tested for HIV, HCV, and HBV from syringes used by survey participants. Results Key informants identified five major drug using locations and estimated the total PWID population size to be between 600 and 2000. Enumerators counted between 35 and 61 individuals present at each of the five bases. Sharing syringes and reusing discarded syringes are common practices. Over half of survey participants (59%) reported past-month syringe sharing (34% used a used syringe and 52% gave away a used syringe). Individuals with higher injection frequency (≥ 21 times weekly) and who injected with four or more people had higher odds of syringe sharing. Of the survey participants reporting sex in the last month (23%), most reported having one partner, but only 12% used condoms. Nearly all women (11/13) reported exchanging sex for drugs and 6/13 reported exchanging sex for money in the last six months. Fifteen percent of participants (all men) reported paying for sex using drugs or money. Of the used syringes, prevalence estimates were 3% (HIV), 2% (HCV), and 9% (HBV). Conclusions Our findings confirm the urgent need to implement harm reduction interventions targeting PWID and to build a strong and enabling legal and policy environment in Ghana to support these efforts.

AIDS Drugs & the Pharmaceutical Industry: A Need For Reform

1991 ◽  
Vol 17 (4) ◽  
pp. 363-410
Author(s):  
Mary T. Griffin
Keyword(s):  
Pharmaceutical Industry ◽  
Research And Development ◽  
Drug Approval ◽  
Hiv And Aids ◽  
Price Regulation ◽  
Drug Industry ◽  
Drug Companies ◽  
Aids Drugs

AbstractThe pharmaceutical industry has long enjoyed substantial profits despite increased requirements for drug approval and various attempts to regulate the industry. Drug companies have avoided effective regulation by blaming high prices on the costs of research and development. The search for drugs effective in combatting HIV and AIDS related illnesses has provided a stark background on which to view the actions and justifications of drug companies. Despite increased cooperation between government and the drug industry and expedited approval of several useful drugs, these drugs are still prohibitively expensive. This Article explores the history and economics of the drug industry and proposes a system of national price regulation for all drugs.

DRUG COMPANIES AND JOURNAL SUPPLEMENTS

The Lancet ◽  
1986 ◽  
Vol 327 (8490) ◽  
pp. 1157 ◽  
Author(s):  
RobertL. Cohen
Keyword(s):  
Drug Companies

scholarly journals Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0223210
Author(s):  
Giselle de Faria Romero Soldi ◽  
Isadora Coutinho Ribeiro ◽  
Cintia Mayumi Ahagon ◽  
Luana Portes Ozório Coelho ◽  
Gabriela Bastos Cabral ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Protease Inhibitors ◽  
Sao Paulo ◽  
Resistance Mutations ◽  
Paulo State ◽  
Drug Resistance Mutations ◽  
São Paulo State ◽  
Major Drug ◽  
Hiv 1

Drug Companies Push Into Central Europe

2006 ◽  
Vol 84 (14) ◽  
pp. 16 ◽  
Author(s):  
MICHAEL MCCOY ◽  
JEAN-FRANÇOIS TREMBLAY
Keyword(s):  
Central Europe ◽  
Drug Companies

Feature

2010 ◽  
Vol 14 (05n06) ◽  
pp. 22-38
Keyword(s):  
Cancer Patients ◽  
Biodiversity Conservation ◽  
Mobile Health ◽  
Health Records ◽  
Drug Companies ◽  
A Priority ◽  
Vein Harvesting

Biodiversity Conservation is Everyone's Business. Search for ASEAN Champions of Biodiversity is On. Drug Companies Reduce Prices of Medicines. SWS: Make Health A Priority, Filipinos Ask Next Leaders. New Vein Harvesting Technology. Mobile Health Records in Malaysia. Faster, Accurately Targeted Radiation Cancer Patients. SingHealth Selects IBM and SAP To Transform HR Processes.

Pharmaceutical Promotion in the Third World

1992 ◽  
Vol 22 (2) ◽  
pp. 417-453 ◽  
Author(s):  
Joel Lexchin
Keyword(s):  
Pharmaceutical Industry ◽  
Health Care Professionals ◽  
Third World ◽  
Marketing Practice ◽  
Professional Groups ◽  
The Third ◽  
Pharmaceutical Manufacturers ◽  
Drug Companies ◽  
Pharmaceutical Promotion ◽  
The Third World

The pharmaceutical industry is motivated by profit and it is the quest for ever larger sales and profits that determines how the industry promotes its products. The author analyzes the methods that drug companies use in marketing their drugs to doctors and consumers, and the consequences in terms of costs and health. Some of the drugs advertised are valuable; others are irrational mixtures, useless or dangerous and should not be on the market. Even for products of proven worth, the companies have a double standard when it comes to promoting them in the Third World. The International Federation of Pharmaceutical Manufacturers Associations does have a Code of Marketing Practice, but major weaknesses in the code render it almost impotent in regulating promotion. When consumers and health care professionals question the tactics of the industry, the response is usually to attack the credibility of the critics rather than to deal with the issues that they raise. Physicians and consumers are strongly influenced by pharmaceutical promotion, with all too predictable results: Doctors prescribe irrationally and consumers develop grossly distorted ideas about the value of modern medications. Reforms to promotional practices are possible, but may be beyond the resources of Third World countries. Achieving these reforms will require the efforts of Third World countries, progressive elements in the pharmaceutical industry, consumer and professional groups and some form of organized international support.

Drug companies withdraw law suit against South Africa

BMJ ◽  
2001 ◽  
Vol 322 (7293) ◽  
pp. 1011-1011 ◽  
Author(s):  
P. Sidley
Keyword(s):  
South Africa ◽  
Drug Companies
Sign in / Sign up

Export Citation Format

Share Document